National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting, 34170-34171 [2023-11227]

Download as PDF 34170 Federal Register / Vol. 88, No. 102 / Friday, May 26, 2023 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of General Medical Sciences; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel; Review of R13 Applications. Date: July 21, 2023. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Institute of General Medical Sciences, Natcher Building, 45 Center Drive, Bethesda, Maryland 20892 (Virtual Meeting). Contact Person: John J. Laffan, Ph.D., Scientific Review Officer, Office of Scientific Review ,National Institute of General Medical Sciences, National Institutes of Health Natcher Building, 45 Center Drive, Room 3AN18J, Bethesda, Maryland 20892, 301– 594–2773, laffanjo@mail.nih.gov. Information is also available on the Institute’s/Center’s home page: www.nigms.nih.gov/, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program No. 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS) Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; RFA–DK–23–006 Advancing Research on Mechanisms and Management of Pain for Diseases and Conditions within NIDDK Mission Areas. Date: July 20–21, 2023. Time: 10:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Democracy II, 6707 Democracy Blvd., Bethesda, MD 20892 (Virtual Meeting). Contact Person: Cheryl Nordstrom, Ph.D., M.P.H., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Democracy II, Suite 7000A, 6707 Democracy Boulevard, Bethesda, MD 20892, 301–402–6711, cheryl.nordstrom@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) Dated: May 23, 2023. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2023–11332 Filed 5–25–23; 8:45 am] BILLING CODE 4140–01–P discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Initial Review Group; Medication Development Research Study Section. Date: July 12, 2023. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications and/or proposals. Place: National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Preethy Nayar, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, 301–443–4577, nayarp2@csr.nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Receptor Binding and Predictive Toxicology. Date: July 12, 2023. Time: 1:00 p.m. to 2:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827–4471, ramadanir@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: May 23, 2023. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: May 22, 2023. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2023–11331 Filed 5–25–23; 8:45 am] National Institutes of Health [FR Doc. 2023–11231 Filed 5–25–23; 8:45 am] BILLING CODE 4140–01–P ddrumheller on DSK120RN23PROD with NOTICES1 amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as VerDate Sep<11>2014 18:14 May 25, 2023 Jkt 259001 National Institute on Drug Abuse; Notice of Closed Meetings BILLING CODE 4140–01–P Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and/or contract proposals and the DEPARTMENT OF HEALTH AND HUMAN SERVICES PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 National Institutes of Health National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as E:\FR\FM\26MYN1.SGM 26MYN1 Federal Register / Vol. 88, No. 102 / Friday, May 26, 2023 / Notices amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Clinical trials and Biomarker studies in StrokeNet. Date: June 27, 2023. Time: 10:00 a.m. to 3:30 p.m. Agenda: To review and evaluate cooperative agreement applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Nilkantha Sen, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, NINDS/NIH, NSC, 6001 Executive Boulevard, Rockville, MD 20852, 301–496–9223, nilkantha.sen@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS.) Dated: May 22, 2023. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2023–11227 Filed 5–25–23; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Federal Emergency Management Agency [Docket ID: FEMA–2023–0009] ddrumheller on DSK120RN23PROD with NOTICES1 Community Disaster Resilience Zones and the National Risk Index Federal Emergency Management Agency, Department of Homeland Security. ACTION: Notice and request for information. and data used for the National Risk Index and any other hazard assessment products; potential improvements to FEMA’s provision of hazard data; the process used to designate community disaster resilience zones; financial and technical assistance for resilience or mitigation projects primarily benefitting community disaster resilience zones; and the community disaster resilience zone project application and certification process. DATES: Comments must be received no later than July 25, 2023. ADDRESSES: Submit comments at www.regulations.gov under Docket ID: FEMA–2023–0009. Follow the instructions for submitting comments. All submissions received must include the agency name and Docket ID, and will be posted, without change, to the Federal eRulemaking Portal at www.regulations.gov and will include any personal information you provide. Therefore, submitting this information makes it public. You may wish to read the Privacy and Security Notice that is available via a link on the homepage of www.regulations.gov. FOR FURTHER INFORMATION CONTACT: Pamela Williams, Assistant Administrator, Grants Programs, Resilience, Federal Emergency Management Agency, FEMA-CDRZRFI@fema.dhs.gov, 202–212–8007. I. Public Participation Interested persons are invited to comment on this notice by submitting written data, views, or arguments using the method identified in the ADDRESSES section. Instructions: All submissions must include the agency name and Docket ID for this notice. All comments received will be posted without change to www.regulations.gov. Commenters are encouraged to identify the number of the specific question or questions to which they are responding. Docket: For access to the docket to read background documents or comments received, go to www.regulations.gov and search for the Docket ID. AGENCY: II. Background The Federal Emergency Management Agency (FEMA) is issuing this notice and request for information (RFI) to seek input from the public on implementation of the Community Disaster Resilience Zones Act of 2022, including updates to the methodology A. Community Disaster Resilience Zones Act The Community Disaster Resilience Zones Act of 2022, Public Law 117–255, 136 Stat. 2363, amended title II of the Robert T. Stafford Disaster Relief and Emergency Assistance Act (42 U.S.C. 5121 et seq.) (Stafford Act) to add a new section 206 (42 U.S.C. 5136) that requires the: (1) maintenance of a natural hazard assessment program and SUMMARY: VerDate Sep<11>2014 18:14 May 25, 2023 Jkt 259001 PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 34171 development and maintenance of products for the public’s use that show the risk of natural hazards through use of risk ratings at the census tract level; and (2) designation of, at the census tract level, community disaster resilience zones based on the natural hazard risk ratings derived from a natural hazard risk product maintained by the natural hazard assessment program. Section 206 also provides FEMA the discretion to: (1) increase the Federal cost share to not more than 90 percent under the Building Resilient Infrastructure and Communities grant program for mitigation projects within, or primarily benefiting, a community disaster resilience zone; (2) provide financial and technical assistance to State, local, Tribal, and Territorial governments for project planning assistance to carry out activities in preparation for a mitigation project; and (3) establish a process for FEMA certification, and provide certification for mitigation projects within, or primarily benefiting, a community disaster resilience zone. B. FEMA National Risk Index In November 2020, FEMA announced the availability of the National Risk Index with limited access to data. On August 16, 2021, FEMA released a full web application which enhanced the data and report functionality.1 The National Risk Index data and application were updated on March 23, 2023 (detailed below). The National Risk Index is a publicly available dataset and online mapping application that identifies the U.S. communities at most risk for 18 different natural hazards. The 18 hazard types evaluated by the National Risk Index were chosen after reviewing FEMA-approved State Hazard Mitigation Plans for all 50 states in early 2016.2 The National Risk Index application visualizes natural hazard risk metrics and includes important data about expected annual losses, social vulnerability, and community resilience.3 All National Risk Index data 1 FEMA, National Risk Index for Natural Hazards, https://www.fema.gov/nri. 2 More information about data availability can be found in FEMA’s National Risk Index Technical Documentation. FEMA, National Risk Index, Technical Documentation, Chapters 5–1 to 5–2 (March 2023), https://www.fema.gov/sites/default/ files/documents/fema_national-risk-index_ technical-documentation.pdf. 3 More information about these risk components can be found in FEMA’s National Risk Index Technical Documentation (March 2023), https:// www.fema.gov/sites/default/files/documents/fema_ national-risk-index_technical-documentation.pdf; FEMA, Data Glossary, https://hazards.fema.gov/nri/ data-glossary (last visited Mar. 23, 2023). E:\FR\FM\26MYN1.SGM 26MYN1

Agencies

[Federal Register Volume 88, Number 102 (Friday, May 26, 2023)]
[Notices]
[Pages 34170-34171]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-11227]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Neurological Disorders and Stroke; Notice 
of Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as

[[Page 34171]]

amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Neurological Disorders 
and Stroke Special Emphasis Panel; Clinical trials and Biomarker 
studies in StrokeNet.
    Date: June 27, 2023.
    Time: 10:00 a.m. to 3:30 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
    Contact Person: Nilkantha Sen, Ph.D., Scientific Review Officer, 
Scientific Review Branch, Division of Extramural Activities, NINDS/
NIH, NSC, 6001 Executive Boulevard, Rockville, MD 20852, 301-496-
9223, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, 
Clinical Research Related to Neurological Disorders; 93.854, 
Biological Basis Research in the Neurosciences, National Institutes 
of Health, HHS.)

    Dated: May 22, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-11227 Filed 5-25-23; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.